-
Nov 27, 2024 | 
radcliffecardiology.com | Harriette Van Spall |Marianna Fontana |Andrew Coats |Milind Y. Desai
Video Published: Views: 34 Likes: 0 Average (ratings) AHA Conference 2024 - Safety and efficacy outcomes of nexiguran ziclumeran (NTLA-2001) in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). Dr Marianna Fontana (University College London, London, UK) joins us onsite at AHA Conference to discuss the findings from the nexiguran ziclumeran for ATTR-CM trial (NCT04601051).
-
Nov 21, 2024 | 
hcplive.com | Milind Y. Desai |Connor Iapoce
Real-world results from the Risk Evaluation and Mitigation Strategy (REMS) program confirmed mavacamten, a cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy (oHCM), maintained a favorable safety profile in more than 6,000 real-world patients.
-
Nov 19, 2024 | 
radcliffecardiology.com | Harriette Van Spall |Mikhail Kosiborod |Julia Grapsa |Milind Y. Desai
AHA Conference 2024 — REALIZE-K: Impact of sodium zirconium cyclosilicate (SZC) on HFrEF patient's potassium levels whilst on spironolactone. Late-Breaker Host, Dr Harriette Van Spall (McMaster University, CA) is joined onsite by Dr Mikhail Kosiborod (Saint Luke's Mid America Heart Institute, US) to discuss the findings from the REALIZE-K Study (NCT04676646; AstraZeneca).
-
Nov 19, 2024 | 
radcliffecardiology.com | Harriette Van Spall |Mikhail Kosiborod |Julia Grapsa |Milind Y. Desai
AHA Conference 2024 — REALIZE-K: Impact of sodium zirconium cyclosilicate (SZC) on HFrEF patient's potassium levels whilst on spironolactone. Late-Breaker Host, Dr Harriette Van Spall (McMaster University, CA) is joined onsite by Dr Mikhail Kosiborod (Saint Luke's Mid America Heart Institute, US) to discuss the findings from the REALIZE-K Study (NCT04676646; AstraZeneca).
-
Aug 22, 2024 | 
jamanetwork.com | Milind Y. Desai |Anjali T. Owens |Kathy E. Wolski
Key PointsQuestion What is the longer-term efficacy of mavacamten in reducing the need for septal reduction therapy (SRT) in patients with obstructive hypertrophic cardiomyopathy (HCM)?
-
May 1, 2024 | 
jacc.org | Milind Y. Desai
Introduction “By far, the greatest danger of artificial intelligence is that people conclude too early that they understand it.” —Eliezer Yudkowsky1 The broad concept of artificial intelligence (AI), of which machine learning (ML) is a key component, is exploding into the world stage at a dizzying pace and is poised to play a pivotal role in predicting outcomes across various fields and industries because of its ability to analyze data, identify patterns, and make predictions or decisions...
-
Jan 25, 2024 | 
medium.com | Milind Y. Desai
The research and development in the field of medical sciences and technology used for diagnosis, treatment, and curing of diseases has immensely benefited the human race. The survival rates and quality of life have greatly improved over the last few decades. The healthcare services include medical consultation, diagnostic services, patient care, nursing care services, IPD and OPD services, and specialty treatments and procedures by medical experts.
-
Oct 23, 2023 | 
cgtlive.com | Milind Y. Desai
This is the second part of an interview with Milind Desai, MD, MBA. For the first part, click here. “The science is there. The process has been operationalized. Now we have to wait and see the downstream ramifications of it.
-
Oct 19, 2023 | 
cgtlive.com | Milind Y. Desai
October 19, 2023The director of the Center for Hypertrophic Cardiomyopathy at the Cleveland Clinic discussed TN-201, an investigational gene therapy for MYBPC3-associated HCM. “...This infusion will top off the missing 30% to 40% of the protein and that is expected to have downstream positive ramifications... If the concept works, then 1 infusion can potentially cure the disease.
-
Oct 13, 2023 | 
healio.com | Regina Schaffer |Milind Y. Desai |Richard Smith
You've successfully added Cardiology: HF/Transplantation to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: A first-in-human phase 1 trial is testing a novel gene therapy for hypertrophic cardiomyopathy.
